Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes.
Saved in:
| Title: | Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes. |
|---|---|
| Authors: | Foss DV; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA.; Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA.; California Institute for Quantitative Biosciences at University of California Berkeley, Berkeley, CA, USA., Muldoon JJ; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Nguyen DN; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA.; Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA.; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Carr D; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA.; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Sahu SU; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA.; Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA.; California Institute for Quantitative Biosciences at University of California Berkeley, Berkeley, CA, USA., Hunsinger JM; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA.; Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA.; California Institute for Quantitative Biosciences at University of California Berkeley, Berkeley, CA, USA., Wyman SK; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA., Krishnappa N; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA., Mendonsa R; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA.; Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA.; California Institute for Quantitative Biosciences at University of California Berkeley, Berkeley, CA, USA., Schanzer EV; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA.; Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA., Shy BR; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA., Vykunta VS; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Allain V; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.; Université de Paris, INSERM UMR976, Hôpital Saint-Louis, Paris, France., Li Z; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA., Marson A; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA. alexander.marson@ucsf.edu.; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. alexander.marson@ucsf.edu.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA. alexander.marson@ucsf.edu.; Parker Institute for Cancer Immunotherapy, University of California San Francisco, San Francisco, CA, USA. alexander.marson@ucsf.edu.; Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA. alexander.marson@ucsf.edu.; Diabetes Center, University of California San Francisco, San Francisco, CA, USA. alexander.marson@ucsf.edu.; UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. alexander.marson@ucsf.edu.; Institute for Human Genetics, University of California San Francisco, San Francisco, CA, USA. alexander.marson@ucsf.edu., Eyquem J; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. justin.eyquem@ucsf.edu.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA. justin.eyquem@ucsf.edu.; Parker Institute for Cancer Immunotherapy, University of California San Francisco, San Francisco, CA, USA. justin.eyquem@ucsf.edu.; Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA. justin.eyquem@ucsf.edu.; UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. justin.eyquem@ucsf.edu.; Institute for Human Genetics, University of California San Francisco, San Francisco, CA, USA. justin.eyquem@ucsf.edu., Wilson RC; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA. rosswilson@berkeley.edu.; Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA. rosswilson@berkeley.edu.; California Institute for Quantitative Biosciences at University of California Berkeley, Berkeley, CA, USA. rosswilson@berkeley.edu. |
| Source: | Nature biomedical engineering [Nat Biomed Eng] 2023 May; Vol. 7 (5), pp. 647-660. Date of Electronic Publication: 2023 Apr 25. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Springer Nature Country of Publication: England NLM ID: 101696896 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2157-846X (Electronic) Linking ISSN: 2157846X NLM ISO Abbreviation: Nat Biomed Eng Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
